推荐应用
Tumor necrosis factor receptor superfamily, member 13C (TNFRSF13C), also known as B-cell-activating factor receptor (BAFFR) or CD268 antigen, is a member of the tumor necrosis factor receptor superfamily. BAFFR promotes B cell survival and is crucial for B cell maturation. BAFF binds to three TNF receptor superfamily members: B-cell maturation antigen (BCMA/TNFRSF17), transmembrane activator and calcium-modulator and cyclophilin ligand interactor (TACI/TNFRSF13B), and BAFF receptor (BAFFR/BR3/TNFRSF13C). These receptors are type III transmembrane proteins without a signal peptide. BAFFR is highly expressed in the spleen, lymph nodes, and resting B cells, and at lower levels in activated B cells, resting CD4+ T cells, the thymus, and peripheral blood leukocytes. BAFF knockout mice lack mature B cells, as do A/WySnJ mice with defects in BAFF-R intracellular signaling, indicating that BAFFR is the critical receptor for BAFF during B lymphopoiesis. It is hypothesized that elevated levels of BAFFR/TNFRSF13C (CD268) may contribute to autoimmune disease pathogenesis by enhancing the survival of autoreactive B cells.
高纯度、高活性、低内毒素、高批间一致性
SDS-PAGE

1μg (R: reducing condition, N: non-reducing condition).
Figure 1.The purity of Human BAFFR is greater than 95% as determined by SDS-PAGE.
SEC-HPLC

The purity of Human BAFFR Fc Chimera Protein is greater than 95% as determined by SEC-HPLC.
ELISA

Immobilized Human BAFFR Fc Chimera Protein at 1.0μg/mL (100μL/well) can bind Biotinylated BAFF Protein, human with EC50 of 1.36-1.52 ng/mL.
-25 ~ -15℃保存,收到货之后有效期1年。
复溶后,无菌条件下,2~8℃保存,7天有效期。复溶后, 无菌条件下,-85 ~ -65℃保存,3个月有效期。
【应用方向】HER2与HER3:ErbB受体家族协同靶向治疗的核心工具蛋白
88
2026-08-31
【应用方向】HER2:抗体药物研发的核心工具蛋白
78
2026-08-31
【应用方向】抗体药研发中常见靶点蛋白及其应用
105
2026-08-31
【应用方向】靶点蛋白在抗体药研发中的应用
86
2026-08-31
【应用方向】GPC3:HCC靶向治疗的核心靶点与药物研发探索
1810
2026-04-24
【应用方向】TROP2:从分子机制到实体瘤靶向治疗的研究进展
1796
2026-04-24
【应用方向】4-1BB-4-1BBL共刺激轴的T细胞活化机制
1086
2026-04-22
【应用方向】TNFR蛋白家族概述
1028
2026-04-21
【应用方向】Klotho蛋白:编织生命之线的抗衰老分子
1176
2026-04-20
【应用方向】药靶明星 | FGFRs家族蛋白解析
888
2026-04-20
【应用方向】解析Fc受体:抗体药物研发的核心靶点与评价基石
907
2026-04-20
【应用方向】FcγR家族:抗体药物研发的基石与核心靶点
945
2026-04-20
【应用方向】CD47-SIRPα轴研究工具与药物开发应用
821
2026-04-20
【技术讲解】ADC药物研究相关靶点汇总
19371
2025-07-30
【应用方向】抗体药筛选的关键—靶点蛋白
11559
2025-07-09





